- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Small Cell Lung Cancer - July 2002
National Cancer Institute®
Last Modified: July 1, 2002
- Expression of metallothionein in lung carcinoma: correlation with histological type and grade.
- Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser
- Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials
- Prognostic factors for patients with small cell lung carcinoma.
- Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer
- Is long term gemcitabine useful in small cell lung cancer?
- Open access follow-up for lung cancer: patient and staff satisfaction.
- [Guideline for chemotherapy of malignant lung cancer]
- Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of
- A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.
- Chemotherapy in small cell lung cancer.
- Limited stage small cell lung cancer.
- Extensive stage small cell lung cancer.
- [Modern chemotherapy in bronchial carcinoma]
- Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific
- Small cell lung cancer: current therapy and promising new regimens.
- Lung cancer: district active treatment rates affect survival.
- Aspirin and lung cancer in women.
- Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma.
Table of Contents
1
UI - 11952858
AU - Theocharis S; Karkantaris C; Philipides T; Agapitos E; Gika A; Margeli
TI -
A; Kittas C; Koutselinis A
Expression of metallothionein in lung carcinoma: correlation with
histological type and grade.
SO - Histopathology 2002 Feb;40(2):143-51
AD - Department of Histology and Embryology, University of Athens, Medical
School, Athens, Greece. theocharis@ath.forthnet.gr
AIMS: Over-expression of cellular metallothionein occurs frequently in
human tumours but the underlying mechanism remains unknown. The aim of
this study was to assess metallothionein expression in cases of lung
carcinoma and to correlate it with histopathological parameters. METHODS
AND RESULTS: Tumour tissue samples from 89 patients with lung carcinoma
were immunostained by the streptavidin-biotin-peroxidase technique,
using a monoclonal antibody against both metallothionein-1 and -2
isoforms. Positive matallothionein immunostaining was prominent in 44
out of 89 (49%) and negative in 45 out of 89 (51%) cases of lung
carcinoma examined. Metallothionein positivity was prominent in 32 out
of 43 (74%) cases of squamous cell lung carcinoma, and in 12 out of 35
(34%) cases of adenocarcinoma, while it was negative in all 11 cases of
small-cell lung carcinoma examined, presenting a statistically
significant difference between the different histological types. The
intensity of metallothionein staining revealed a statistically
significant difference between the squamous cell and adenocarcinoma
cases examined. The pattern and extent of metallothionein staining in
tumour cells and the expression of metallothionein in stromal cells were
not correlated with histopathological parameters (type and grade) in
metallothionein-positive cases of lung carcinoma examined. No
association was found between metallothionein expression and lymph node
status in the examined cases of lung carcinoma. CONCLUSIONS: Our
findings indicate that expression of metallothionein was evident in
squamous cell lung carcinoma and adenocarcinoma, but absent in
small-cell lung carcinoma, supporting evidence for participation of this
protein in the biological mechanisms underlying the carcinogenic
evolution in the lung.
2
UI - 12044890
AU - Wessel I; Jensen LH; Renodon-Corniere A; Sorensen TK; Nitiss JL; Jensen
TI -
PB; Sehested M
Human small cell lung cancer NYH cells resistant to the
bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser
mutation in the Walker A ATP binding site of topoisomerase II alpha.
SO - FEBS Lett 2002 Jun 5;520(1-3):161-6
AD - Department of Pathology, Laboratory Center, Rigshospitalet 5431, DK-2100
Copenhagen, Denmark.
Bisdioxopiperazine anti-cancer agents are catalytic inhibitors of
topoisomerase II which by unknown means lock the enzyme in a closed
clamp form and inhibit its ATPase activity. In order to demarcate a
putative pharmacophore, we here describe a novel Tyr165Ser mutation in
the enzyme's Walker A ATP binding site leading to specific
bisdioxopiperazine resistance when transformed into a
temperature-conditional yeast system. The Tyr165Ser mutation differed
from a previously described Arg162Gln by being heterozygous and by
purified Tyr165Ser enzyme being drug-resistant in a kinetoplast DNA
decatenation enzymatic assay. This suggested dominant nature of
Tyr165Ser was supported by co-transformation studies in yeast of
plasmids carrying wild type and mutant genes. These results enable a
model of the bisdioxopiperazine pharmacophore using the proposed
asymmetric ATP hydrolysis of the enzyme.
3
UI - 10931451
AU - Paesmans M; Sculier JP; Lecomte J; Thiriaux J; Libert P; Sergysels R;
TI -
Bureau G; Dabouis G; Van Cutsem O; Mommen P; Ninane V; Klastersky J
Prognostic factors for patients with small cell lung carcinoma: analysis
of a series of 763 patients included in 4 consecutive prospective trials
with a minimum follow-up of 5 years.
SO - Cancer 2000 Aug 1;89(3):523-33
AD - Institut Jules Bordet, Brussels, Belgium.
BACKGROUND: The purposes of this study were to identify prognostic
factors for response to chemotherapy, overall survival, and long term
survival of patients with small cell lung carcinoma and to construct a
classification of patients on the basis of their expected overall
survival. METHODS: In the 763 patients registered in 4 consecutive
clinical trials conducted by the European Lung Cancer Working Party from
1982 to 1993, the impact of 21 pretreatment variables assessable in a
routine practice was analyzed for the various outcomes with a minimum
follow-up of 5 years. RESULTS: The key prognostic role of disease extent
was confirmed for all the outcomes. Additional independent prognostic
factors for response to chemotherapy were gender, neutrophil count, and
hemoglobin level; for overall survival, these factors were Karnofsky
performance status, gender, and neutrophil count. Recursive partitioning
and amalgamation algorithms (RECPAM) analysis classified patients into 4
groups, taking into consideration disease extent, Karnofsky performance
status, age, gender, and neutrophil count. Median survival times for the
4 groups were 60, 47, 36, and 28 weeks, respectively. For long term
survival, defined as a minimum survival of 2 years (9% of the patients),
Karnofsky performance status was the only independent predictive factor,
along with the achievement of a complete response (if this was taken
into consideration). Small cell lung carcinoma remained the main cause
of death among these patients. Cure was infrequent, with only 14
patients alive and disease free at 5 years (1.8%). CONCLUSIONS: In this
study the long term prognosis associated with small cell lung carcinoma
was poor. The well-known prognostic values of disease extent and
Karnofsky performance status were confirmed, but the authors also
identified age and gender (which are more controversial) as independent
characteristics, in addition to citing the role of complete response in
the attainment of long term survival. The independent role of
neutrophils observed by the authors. must be validated by further
studies. Copyright 2000 American Cancer Society.
4
UI - 11900243
AU - Watine J
TI -
Prognostic factors for patients with small cell lung carcinoma.
SO - Cancer 2002 Jan 15;94(2):576-8
5
UI - 11955649
AU - Trojan A; Tun-Kyi A; Odermatt B; Nestle FO; Stahel RA
TI -
Functional detection of epithelial cell adhesion molecule specific
cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer
and in healthy donors.
SO - Lung Cancer 2002 May;36(2):151-8
AD - Division of Oncology, Department of Internal Medicine, University
Hospital Zurich, Ramistrasse 100, 8091, Switzerland.
andreas.trojan@dim.usz.ch
Epithelial cell adhesion molecule (Ep-CAM) derived antigenic peptides
have been identified that can be recognized by cytotoxic T lymphocytes
(CTL) in a major histocompatibility complex (MHC) class I restricted
fashion. Thus, altered expression of Ep-CAM in a variety of human tumors
might render a potential target for T cell mediated therapy. We have
examined, whether the novel HLA-A*0201 restricted peptide ILYENNVIT
(184-192) corresponding to Ep-CAM and one heteroclitic modified variant
peptide previously demonstrated to be immunogenic in the human system
can elicit antigen specific CTL responses in HLA-A2 positive patients
with history of Ep-CAM expressing cancer of lung and colon. Specific CTL
recognition of T2 target cells pulsed with the native peptide as well as
of the lung cancer cell line A549 indicates that an appropriate T cell
repertoire can be expanded from peripheral blood from patients in
clinical remission and with advanced cancer. Despite an overall low
frequency, peptide specific precursor CTLs could be readily expanded
from peripheral blood from 6/8 patients that were diagnosed previously
with Ep-CAM expressing lung cancer and 4/8 control individuals (2/5
healthy donors and 2/3 colon cancer patients). CTLs from three of five
lung cancer patients tested also lyzed the HLA-A2(+) and Ep-CAM
expressing lung cancer cell line A549. We did not detect an increased
frequency of pCTLs after peripheral blood monocytes (PBMCs) were
stimulated with the heteroclitic compound peptide. The results of our
study indicate that Ep-CAM specific precursor CTL can be expanded in
vitro and a specific T cell response against this epitope can be
elicited in patients at various stages of lung cancer.
6
UI - 11955659
AU - Dediu M
TI -
Is long term gemcitabine useful in small cell lung cancer?
SO - Lung Cancer 2002 May;36(2):217-8
7
UI - 11824875
AU - Adlard JW; Joseph J; Brammer CV; Gerrard GE
TI -
Open access follow-up for lung cancer: patient and staff satisfaction.
SO - Clin Oncol (R Coll Radiol) 2001;13(6):404-8
AD - Yorkshire Regional Centre for Cancer Treatment, Cookridge Hospital,
Leeds, UK.
The majority of patients with lung cancer have incurable disease from
presentation and a survival measured in months. Treatments offered to
these patients are aimed at the palliation of symptoms with either
radiotherapy or chemotherapy, or with supportive measures. It has been
traditional to offer regular outpatient follow-up after initial
palliative treatment. Further treatment options, which may be limited,
are usually reserved for the recurrence of troublesome symptoms. A pilot
'open access' lung cancer clinic has been set up. Rather than have
regular follow-up at the hospital, patients who have completed initial
palliative treatments are discharged to the community with follow-up by
their general practitioner and Macmillan nurse. Review at the open
access clinic can be arranged at short notice if requested by the
patient, carers, general practitioner or Macmillan nurse. The outcomes
and level of satisfaction of patients, their relatives and staff to this
method of follow-up were found to be positive. Open access follow-up may
be useful for many patients after the completion of initial palliative
treatment.
8
UI - 12109452
AU - Yamamoto N; Fukuoka M
TI -
[Guideline for chemotherapy of malignant lung cancer]
SO - Gan To Kagaku Ryoho 2002 Jun;29(6):985-1007
9
UI - 11822755
AU - Kao A; Shiun SC; Hsu NY; Sun SS; Lee CC; Lin CC
TI -
Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell
lung cancer. Relationship to chemotherapy response (six courses of
combination of cisplatin and etoposide) and p-glycoprotein or multidrug
resistance related protein expression.
SO - Ann Oncol 2001 Nov;12(11):1561-6
AD - Department of Nuclear Medicine, China Medical College Hospital,
Taichung, Taiwan. albertkaotw@yahoo.com.tw
AIMS: This is a retrospective and adaptive randomization study. The
purpose of this study was to evaluate the relationship between
technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) chest-imaging
results, chemotherapy response and P-glycoprotein (Pgp) or multidrug
resistance related protein (MRP) expression in small-cell lung cancer
(SCLC). PATIENTS AND METHODS: Before chemotherapy, 30 patients (11
females, 19 males, ages: 52-69 years) with SCLC, including 14 extensive
diseases without localized problems and 16 limited diseases in excess of
solitary pulmonary nodule, underwent early chest imaging, including
visual interpretation and quantitative analyses of tumor uptake ratio
(TUR), 10 minutes after intravenous injection of Tc-99m MIBI.
Immunohistochemical analyses were performed, using multiple
nonconsecutive sections of the biopsy specimens, to detect Pgp and MRP
expressions. Chemotherapy response was evaluated in the third month
after completion of treatment by clinical and radiological methods.
RESULTS: All 15 (100%) of the SCLC patients with complete or partial
response had positive Tc-99m MIBI chest SPECT results, but negative ones
for both Pgp and MRP expression. Twelve of the 15 (80%) SCLC patients
with no response or progressive disease had negative Tc-99m MIBI chest
SPECT results and were positive for either Pgp or MRP expression (P <
0.05). Negative Tc-99m MIBI chest SPECT results predicted complete or
partial response. The TUR of patients with complete or partial response
(1.91 +/- 0.29 with a 95% confidence interval (95% CI): 1.75-2.07) was
significantly higher than that of patients with no response or
progressive disease (1.19 +/- 0.28 with a 95% CI: 1.04-1.35).
CONCLUSION: Tc-99m MIBI chest images are a potential tool for
understanding Pgp and MRP expressions in SCLC and for predicting patient
chemotherapy response.
10
UI - 11822756
AU - Huisman C; Postmus PE; Giaccone G; Smit EF
TI -
A phase I study of sequential intravenous topotecan and etoposide in
lung cancer patients.
SO - Ann Oncol 2001 Nov;12(11):1567-73
AD - Department of Pulmonary, University Hospital Vrije Universiteit,
Amsterdam, The Netherlands.
PURPOSE: The topoisomerase I inhibitor topotecan (T) and the
topoisomerase II inhibitor etoposide (E) are active drugs in lung
cancer. The complementary functions of their targets may suggest benefit
from the combined use of these agents but drug scheduling has been shown
to play a critical role in preclinical models. To establish the optimal
schedule and assess the impact of sequential administration of the
combination of T and E, we conducted a dose finding study of sequential
intravenous T and E in a four-weekly-schedule in relapsed lung cancer
patients. PATIENTS AND METHODS: The importance of drug sequence was
assessed in consecutive patients throughout all dose levels; patients
received in the first course either T followed by E (the TE group: T on
days 1-3 and E on days 4-6) or E before T (the ET group: F on days 1-3
and Ton days 4-6). The sequence of Tand E was alternated in the
successive courses. In this crossover design, each patient served as his
own control for analysis of hematological toxicity in which TE sequence
was compared to that of the ET sequence. Moreover, hematological
toxicity after the first course was compared between the TE and the ET
groups. The starting dose was T/E 0.75/75 mg/m2 at dose level 1and dose
escalation was planned to T/E 1.00/75 mg/nm2 at dose level 2, T/E
1.00/100 mg/m2 at dose level 3, T/E 1.25/100 mg/m2 at dose level 4 and
T/E 1.50/100 mg/m2 at dose level 5. Nineteen patients (small-cell lung
cancer 7, non-small-cell lung cancer 11, mesothelioma 1 patient) were
included. RESULTS: The principal toxicity was myelosuppression,
primarily neutropenia and thrombocytopenia. At dose level 3 several
grade 4 toxicities were observed. DLT (febrile neutropenia) occurred in
two patients, one in the TE and one in the ET group and precluded
further dose escalation. There was no significant difference in WBC and
platelet nadirs during the first course between the TE and the ET group.
The influence of the sequence of administration of topotecan and
etoposide was calculated by comparing the nadir values of cycles I and
II for each patient. For none of the dose levels, a significant
sequence-dependent effect could be detected. The MTD was reached at the
doses of 100 mg/m2 topotecan and 75 mg/m2 etoposide. No objective
responses were seen. CONCLUSION: Although the combined use of
topoisomerase I and II inhibitors is attractive on theoretical grounds,
excessive myelosuppression prevents substantial dose escalation.
11
UI - 11829085
AU - Osterlind K
TI -
Chemotherapy in small cell lung cancer.
SO - Eur Respir J 2001 Dec;18(6):1026-43
AD - Dept of Oncology, Herlev University Hospital, Denmark.
Chemotherapy is the backbone in the treatment of small cell lung cancer
(SCLC) and radiotherapy is an important adjunct in limited stage
disease. The role of chest irradiation is now documented in three
meta-analysis, based on the same body of data. Trials on timing,
scheduling and fractionation could have followed a more stringent
development line but altogether, the highest efficacy seems to be
obtained with early, concurrent twice-daily chest irradiation. Patients
in complete remission should have prophylactic cranial irradiation,
which reduces the risk of brain metastases and of death from SCLC. Four
series of chemotherapy seem to be sufficient in limited-stage disease
while six is recommended in extensive disease. The combination of
etoposide plus cis- or carboplatin is appropriate in both stages and
addition of other agents has no clinically important impact on the
survival. Use of haematological growth factors such as granulocyte
colony stimulating factor (G-CSF) and granulocyte macrophage colony
stimulating factor (GM-CSF) may enable higher doses or more frequent
dosage. Three randomized trials on GM-CSF showed a negative outcome
while G-CSF support may result in better survival rates, but a more
cost-efficient policy must be found. High-dose chemotherapy plus
haematological stem-cell support is still under investigation but
disappointing long-term survival rates means there is not much optimism
for this strategy. New strategies in general are requested in the
treatment of extensive-stage disease and of elderly patients. Phase II
trials suggest that good-risk patients with extensive disease should be
treated aggressively, intermediate-risk patients more gently, and
palliation must be the primary aim in the treatment of poor-risk
patients. In elderly patients impressive survival rates are obtained
with 3-4 series of chemotherapy and radiation delivered in 5-10
fractions. A number of new agents are active but more trials are
required before each has found a place, if any, in the treatment of
small cell lung cancer. To conclude, the randomized trial is still an
important instrument in clinical oncology, and trials in small cell lung
cancer must be large, which is why the cooperation of organizations and
multicentres is urgent.
12
UI - 12057141
AU - Murray N; Sheehan F
TI -
Limited stage small cell lung cancer.
SO - Curr Treat Options Oncol 2001 Feb;2(1):63-70
AD - British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British
Columbia, Canada V5Z 4E6.
The management of limited stage small cell lung cancer begins with a
firm pathologic diagnosis and careful staging. Patients with adequate
pulmonary function, ambulatory performance status, and no evidence of
metastatic disease outside a "tolerable" local radiotherapy volume
should have consultation from both medical and radiation oncology
disciplines for planning of integrated therapy. The chemotherapy
prescription recommended is cisplatin plus etoposide at standard doses
for four chemotherapy cycles. Thoracic irradiation should be
administered concurrently with the first or second cycle of cisplatin
and etoposide. Patients with complete response and excellent partial
response should receive prophylactic cranial irradiation after
completion of all chemotherapy.
13
UI - 12057142
AU - Niell HB
TI -
Extensive stage small cell lung cancer.
SO - Curr Treat Options Oncol 2001 Feb;2(1):71-6
AD - Van Vleet Cancer Center, University of Tennessee-Memphis, 3N Dunlap,
Memphis, TN 38163, USA.
Small cell lung cancer is a rapidly proliferating, biologically
aggressive form of lung cancer that has a short survival without
treatment. Chemotherapy is the foundation of the therapeutic approach to
patients with small cell lung cancer. Most patients present with
extensive disease, and, although few patients are cured, significant
improvement in survival is possible with modern chemotherapy. The role
of radiation therapy in extensive disease is palliative, and surgery has
little role in patient management. The standard chemotherapy regimen for
patients with small cell lung cancer has become either cisplatin or
carboplatin with etoposide. Second-line chemotherapy regimens are
moderately effective in patients previously responding to initial
chemotherapy. Newer chemotherapy agents show promise, but few randomized
trials have been completed in extensive disease. Physicians should be
encouraged to include their patients with extensive small cell lung
cancer in the evolving clinical trials.
14
UI - 11963726
AU - Schalhorn A
TI -
[Modern chemotherapy in bronchial carcinoma]
SO - Internist (Berl) 2002 Mar;43(3):416-30
AD - Medizinische Klinik III, Ludwig-Maximilians-Universitat, Klinikum
Grosshadern, Marchioninistrasse 15, 81377 Munchen.
15
UI - 11985730
AU - Mall JW; Schwenk W; Philipp AW; Meyer-Kipker C; Mall W; Muller J;
TI -
Pollmann C
Serum vascular endothelial growth factor levels correlate better with
tumour stage in small cell lung cancer than albumin, neuron-specific
enolase or lactate dehydrogenase.
SO - Respirology 2002 Jun;7(2):99-102
AD - Department of General, Vascular and Thoracic Surgery, Medical Faculty of
the Humboldt University, Berlin, Germany. julianmall@hotmail.com
OBJECTIVE: Vascular endothelial growth factor (VEGF) is an important
cytokine in the process of angiogenesis. Elevated serum levels of the
cytokine may determine cancer patients who will benefit from adjuvant
anti-angiogenic therapy in the future. To correlate serum levels of VEGF
with tumour stage and established prognostic markers in patients with
small cell lung cancer (SCLC), a prospective study was performed on 70
patients (51 male, 19 female) with histologically proven SCLC were
enrolled into the study. Staging of the disease included clinical
investigation, bronchoscopy, chest X-ray, thoracic computed tomography
and ultrasound. The patients were grouped into five stages according to
the Marburg classification (very limited disease (VLD), limited disease
(LD), extensive disease I (EDI), extensive disease II (EDII) and
extensive disease III (EDIII)). Prior to treatment, a 10 mL serum sample
from each patient was examined by ELISA to quantify levels of VEGF and
neuron-specific enolase (NSE). Lactate dehydrogenase (LDH) and albumin
levels were determined by photomorphometric analysis. Statistical
analysis was performed using the Waller-Duncan k ratio t-test and
Pearson's correlation test. RESULTS: Serum VEGF levels correlated well
with tumour stage (P < 0.0001). Albumin levels were not correlated with
tumour stage, but levels of NSE and LDH increased with stage
progression. When patients were divided into two groups (VLD and LD vs
EDI-III), VEGF levels were significantly lower in the initial stages of
the disease compared with extensive disease (P < 0.0001). Serum levels
of VEGF correlated better with tumour stage than did concentrations of
NSE, LDH or albumin. CONCLUSION: Serum VEGF levels may serve as an
additional prognostic marker in the course of patients with SCLC.
Further studies are needed to determine whether these patients may
benefit from additional anti-angiogenic therapy in the future.
16
UI - 12065796
AU - Okuno SH; Jett JR
TI -
Small cell lung cancer: current therapy and promising new regimens.
SO - Oncologist 2002;7(3):234-8
AD - Mayo Clinic, Rochester, Minnesota 55905, USA. okuno.scott@mayo.edu
In this review, we cover current therapy and promising new regimens and
highlight areas where improvement is needed in the management of small
cell lung cancer.
17
UI - 12011196
AU - Cartman ML; Hatfield AC; Muers MF; Peake MD; Haward RA; Forman D;
TI -
Yorkshire Cancer Management Study Group, Northern and Yorkshire Cancer
Registry and Information Service (NYCRIS), UK
Lung cancer: district active treatment rates affect survival.
SO - J Epidemiol Community Health 2002 Jun;56(6):424-9
AD - NYCRIS, Leeds, UK.
STUDY OBJECTIVE: This study investigates variation in management and
treatment of lung cancer patients and determines the impact of any
variation in treatment on survival. DESIGN: A retrospective study of
population based data held by the Northern & Yorkshire Cancer Registry
and Information Service (NYCRIS), comparing active treatment rates for
lung cancer with survival by districts. SETTING The then 17 districts in
Yorkshire and South Humber, England. PATIENTS: 22 654 patients
registered with lung cancer between 1986 and 1994 and followed up until
end of 1996. RESULTS: The overall rates of active treatment (surgery,
radiotherapy, and chemotherapy) varied between districts from 37% to
56%. One year survival (with 95% CI) was significantly better in the
districts with highest rates of active treatment 23% (22% to 24%)
compared with 19% (17% to 20%) for those with lowest treatment rates.
Non-small cell lung cancer patients (55%) in the districts with highest
active treatment rates had an age adjusted relative risk of death during
the follow up period, relative to risk of death in the districts with
the lower treatment rates of 0.88 (0.83 to 0.92). Clinically diagnosed
patients (34%) had an age adjusted RR of 0.92 (0.86 to 0.96). RR in
small cell cancer (11%) was not significant. CONCLUSION: This study has
shown wide variations in the rates of active treatment for lung cancer
patients within districts across one large region of England. Active
treatment was strongly associated with improved survival, especially in
non-small cell lung cancer.
18
UI - 12085255
AU - Akhmedkhanov A; Toniolo P; Zeleniuch-Jacquotte A; Koenig KL; Shore RE
TI -
Aspirin and lung cancer in women.
SO - Br J Cancer 2002 Jul 1;87(1):49-53
AD - Department of Obstetrics and Gynecology, New York University School of
Medicine, 550 First Avenue, NBV-9E2, New York, NY 10016, USA.
akhmea01@med.nyu.edu
The association between aspirin use and lung cancer risk in women was
examined in a case-control study nested in the New York University
Women's Health Study, a large cohort in New York. Case subjects were all
the 81 incident lung cancer cases who had provided information about
aspirin use at enrollment and during the 1994-1996 follow up. Ten
controls per case were randomly selected from among study participants
who matched a case by age, menopausal status, and dates of enrollment
and follow-up. Relative to no aspirin use, the odds ratio for lung
cancer (all histological sub-types combined) among subjects who reported
aspirin use three or more times per week for at least 6 months was 0.66
(95% confidence interval 0.34-1.28), after adjustment for smoking and
education. A stronger inverse association was observed in analyses
restricted to non-small cell lung cancer (adjusted odds ratio 0.39, 95%
confidence interval 0.16-0.96). These results suggest that regular
aspirin use might be inversely associated with risk of lung cancer in
women, particularly the non-small cell sub-type. Copyright 2002 Cancer
Research UK
19
UI - 12115391
AU - Nakahara Y; Mochizuki Y; Miyamoto Y; Tanaka A; Kawamura T; Sasaki S;
TI -
Nakahara Y; Katsura Y
Mental state as a possible independent prognostic variable for survival
in patients with advanced lung carcinoma.
SO - Cancer 2002 Jun 1;94(11):3006-15
AD - Department of Respiratory Medicine, Himeji National Hospital,
Himeji-city, Japan. nkhr@meg.winknet.ne.jp
BACKGROUND: Although psychologic factors have been reported to influence
the progression of cancer, this theory remains controversial. A
prospective study of patients with advanced lung carcinoma was performed
to explore the influence of the patient's mental state on survival.
METHODS: The patient's mental state was assessed with the Tokyo
University Egogram. In a preliminary study, the egograms of long-term
survivors (survival > 3 years) with TNM Stage IIIB or Stage IV lung
carcinoma were compared with the egograms of consecutive, newly
diagnosed lung carcinoma patients (controls). Next, in a prospective
study, 123 patients with nonsmall cell lung carcinoma and 56 patients
with small cell lung carcinoma (Stage IIIB or Stage IV; Eastern
Cooperative Oncology Group performance status of 0 or 1) completed the
egogram. Based on the results of the preliminary study, the subjects in
the prospective study were divided into Group A (Free Child [FC] >or=
50th percentile and Adapted Child [AC] < 50th percentile) and Group B
(FC < 50 percentile or AC >or= 50 percentile). The survival of the two
groups was compared. The Cox proportional hazards model was used to
determine the joint effect of the patient's mental state and other
prognostic factors. RESULTS: In the preliminary study, the FC score of
the long-term survivors was significantly higher and the AC score was
significantly lower than those of the controls. In the prospective
study, the survival of Group A was significantly longer than that of
Group B both in the nonsmall cell lung carcinoma and small cell lung
carcinoma patients (P = 0.002 and P = 0.005, respectively, by the
log-rank test). Multivariate analysis demonstrated that after adjustment
for clinical factors, being in Group A was a significant predictor of
survival both in the nonsmall cell and small cell lung carcinoma
patients. CONCLUSIONS: The results of the current study demonstrate that
the mental state of the patient as assessed by the egogram may have
prognostic significance in patients with advanced lung carcinoma.
Copyright 2002 American Cancer Society.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
